Boyer Olivia, Baudouin Véronique, Bérard Étienne, Biebuyck-Gougé Nathalie, Dossier Claire, Guigonis Vincent, Audard Vincent, Klifa Roman, Leroy Valérie, Ranchin Bruno, Roussey Gwenaëlle, Samaille Charlotte, Tellier Stéphanie, Vrillon Isabelle
Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Necker-Enfants-malades, institut Imagine, université de Paris, 149, rue de Sèvres, 75015 Paris, France.
Service de néphrologie pédiatrique, centre de référence du syndrome néphrotique idiopathique de l'enfant et de l'adulte, hôpital Robert-Debré, institut Imagine, université de Paris, 48, boulevard Sérurier, 75935 Paris cedex 19, France.
Nephrol Ther. 2020 May;16(3):177-183. doi: 10.1016/j.nephro.2019.09.007. Epub 2020 Apr 8.
The specific treatment of idiopathic nephrotic syndrome is based on corticosteroid therapy and/or steroid-sparing immunosuppressive agents in children who are steroid-dependant or frequent relapsers (60-70 %). Patients have an increased infectious risk not only related to the disease during relapses (hypogammaglobulinemia and urinary leakage of opsonins) but also to treatments (corticosteroids or immunosuppressive agents) in period of remission. Vaccination is therefore particularly recommended in these patients. Potential vaccine risks are ineffectiveness, induction of vaccine disease and relapse of idiopathic nephrotic syndrome. Only live vaccines expose to the risk of vaccine disease: they are in general contra-indicated under immunosuppressive treatment. The immunogenicity of inactivated vaccines is reduced but persists. The immunogenic stimulus of vaccination may in theory trigger a relapse of the nephrotic syndrome. Nevertheless, this risk is low in the literature, and even absent in some studies. The benefit-risk ratio is therefore in favor of vaccination with respect to the vaccination schedule for inactivated vaccines, with wide vaccination against pneumococcus and influenza annually. Depending on the context and after expert advice, immunization with live vaccines could be discussed if residual doses/levels of immunosuppressive treatments are moderate and immunity preserved.
特发性肾病综合征的特异性治疗基于对激素依赖或频繁复发(60%-70%)儿童的皮质类固醇治疗和/或激素替代免疫抑制剂治疗。患者不仅在复发期间(低丙种球蛋白血症和调理素尿漏)因疾病而感染风险增加,而且在缓解期因治疗(皮质类固醇或免疫抑制剂)而感染风险增加。因此,特别推荐对这些患者进行疫苗接种。潜在的疫苗风险包括疫苗无效、引发疫苗相关疾病以及特发性肾病综合征复发。只有活疫苗存在引发疫苗相关疾病的风险:一般在免疫抑制治疗期间禁忌使用。灭活疫苗的免疫原性降低但仍然存在。理论上,疫苗接种的免疫原性刺激可能引发肾病综合征复发。然而,文献中这种风险较低,甚至在一些研究中不存在。因此,就灭活疫苗的接种计划而言,获益风险比有利于接种疫苗,建议每年广泛接种肺炎球菌疫苗和流感疫苗。根据具体情况并在专家建议后,如果免疫抑制治疗的残留剂量/水平适中且免疫力得以保留,可以讨论接种活疫苗。